Asia
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
There are over 170 COVID-19 vaccine candidates at various stages of development, and all but a few of them take the traditional intramuscular approach. But could intranasal delivery ease the logistical nightmare we face in exterminating the pandemic across the globe?
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
The Serum Institute of India (SII) has agreed to produce and deliver up to an additional 100 million doses of an approved COVID-19 vaccine for citizens of India and neighboring low- and middle-income countries as part of a collaboration with Gavi and the Bill & Melinda Gates Foundation.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.
The company plans to submit its biologic license application (BLA) to China’s National Medical Products Administration (NMPA) and other regulators worldwide.
XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, now has $318.8 million more to bring drug development into the future.
Starting with just $11 million seed in 2015, investors have proven their faith in InvestiBio with their increasing financial support.
PRESS RELEASES